Egetis Therapeutics Agrees to Sell Voucher for $190M
Egetis Therapeutics agreed to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $190M (approximately SEK 1,900M). Former RTTI owners are entitled to approximately 50% of net proceeds; closing is subject to customary conditions, including HSR waiting-period expiration.
Egetis Therapeutics agreed to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $190M (approximately SEK 1,900M). Former RTTI owners are entitled to approximately 50% of net proceeds; closing is subject to customary conditions, including HSR waiting-period expiration.Mat…